Haroon Hyder, MD
Family Medicine · Richmond, VANPI 1740470483
Payments from drug & device makers
Across 139 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$570
- Novo Nordisk$316
- AstraZeneca$191
- Amgen$134
- Medtronic$104
- Neurelis, Inc.$98
- plus $704 from 25 others
What the payments were for
- Food & beverage$2,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $570 |
| Novo Nordisk | 22 | $316 |
| AstraZeneca(2 entities) | 14 | $191 |
| Amgen | 9 | $134 |
| Medtronic | 2 | $104 |
| Neurelis, Inc. | 1 | $98 |
| Bayer | 6 | $82 |
| Lilly USA, LLC | 6 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Boehringer Ingelheim | 3 | $37 |
| Johnson & Johnson | 3 | $36 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Edwards Lifesciences | 2 | $29 |
| Merck | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $26 |
| Mylan Specialty L.p. | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Abbott | 1 | $20 |
| GSK | 1 | $19 |
| Pfizer | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Novartis | 1 | $13 |
| Grifols USA, LLC | 1 | $12 |
| Clarus Therapeutics Inc. | 2 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,117 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $68,504 |
| TrulicityDulaglutide | 61 | $66,197 |
| MounjaroTirzepatide | 58 | $61,628 |
| JardianceEmpagliflozin | 30 | $44,107 |
| EliquisApixaban | 45 | $39,827 |
| XareltoRivaroxaban | 22 | $26,035 |
| JanuviaSitagliptin Phosphate | 15 | $18,514 |
| Levothyroxine Sodium | 276 | $2,414 |
| Olmesartan Medoxomil | 119 | $2,301 |
| Lidocaine | 21 | $2,080 |
| Atorvastatin Calcium | 252 | $1,953 |
| Amlodipine Besylate | 312 | $1,797 |
| Losartan Potassium | 192 | $1,580 |
| Simvastatin | 201 | $1,390 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $1,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $79 | $127,824119 claims |
| Novo NordiskOzempic | $316 | $68,50449 claims |
| Boehringer IngelheimJardiance | $37 | $44,10730 claims |
| PfizerEliquis | $17 | $39,82745 claims |
| Johnson & JohnsonXarelto | $36 | $26,03522 claims |
| MerckJanuvia | $29 | $18,51415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Banks TurnerRichmond$74K
- James FosterRichmond$27K
- George MaughanRichmond$21K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.